TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. IL2 is a cytokine signaling molecule that can limit immune suppression.

France

https://clinicaltrials.gov/ct2/show/NCT01988506?recrs=a&cond=ITP&draw=2&rank=41

Recruiting